Celldex Therapeutics reported $66.39M in Ordinary Share Capital for its fiscal quarter ending in June of 2025.


Ordinary Share Capital Change Date
AbbVie USD 18M 0 Dec/2024
Amgen USD 538M 33.04B Jun/2025
Bristol-Myers Squibb USD 2.04B 1.74B Jun/2025
Celldex Therapeutics USD 66.39M 66.33M Jun/2025
Glaxosmithkline GBP 4.15B 2.8B Jun/2025
Pfizer USD 5.68B 5.2B Jun/2025
Roche Holding CHF 107M 0 Jun/2024